Clinical Trials Browser

Phase 1 × niraparib × Breast × Clear all

NCT04481113 2026-01-29

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Phase 1 Completed

Unilateral Breast Neoplasms

NCT04991480 2026-01-27

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Active not recruiting

BreastGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT03945721 2025-09-29

UNITY

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT03329937 2025-01-08

Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer

Phase 1 Completed

21 enrolled 12 charts

Breast Neoplasms

NCT03154281 2024-08-01

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Phase 1 Completed

14 enrolled 12 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT05261269 2023-12-13

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer

Phase 1 Completed

HER2-negative Metastatic Breast Cancer

NCT04762901 2022-04-26

LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT04764084 2021-02-21

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

Phase 1 Unknown

BreastGastrointestinal

Breast Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma